DaVita Inc. (DVA) Earnings Call Transcript & Summary

May 5, 2020

New York Stock Exchange US Health Care Health Care Providers and Services earnings 62 min

Earnings Call Speaker Segments

Jim Gustafson

executive
#1

Thanks, and welcome, everyone, to the conference call for our first quarter. We're grateful that you keep taking an interest in our company. I'm Jim Gustafson, and I serve as Vice President of Investor Relations. Joining me remotely today are Javier Rodriguez, our CEO; Joel Ackerman, our CFO; and LeAnne Zumwalt, Group Vice President. I'd like to point out that on this call we'll be making forward-looking statements as defined under the federal securities laws. Each of those statements carries known and unknown risks and uncertainties, and those could make actual results differ materially from what the forward-looking statements describe. To learn more about these risks and uncertainties, please see the earnings press release for our first quarter and our SEC filings, including our most recent annual report on Form 10-K and the subsequent quarterly report for the first quarter of 2020 on Form 10-Q, which is going to be filed today. Our forward-looking statements rest on information available to us at present, and we neither intend nor undertake any duty to update them. We'd also like to remind you that we will discuss some non-GAAP financial measures during this call. A reconciliation of these non-GAAP financial measures to comparable GAAP financial measures appears in our earnings press release submitted to the SEC and available on our website. I'll now hand the call over to Javier Rodriguez.

Javier Rodriguez

executive
#2

Thank you, Jim, and good afternoon to all of you. I hope you and your families are in good health. To start, I want to voice my heartfelt gratitude to the 65,000 nurses, patient care technicians, social workers, dietitians and other caregivers across the globe — among them many nonclinical workers — who stand on the front lines of care alongside our physician partners. These individuals embody what DaVita means: giving life during this worldwide crisis. Their bravery and commitment to serving others energizes and inspires us. I'd also like to extend that thanks to every health care organization and caregiver around the world. On today's call, I'll cover 3 topics: how we are responding to the crisis; what COVID has done to our business; and the choices we've made regarding the Cares Act. At Capital Markets, I spoke about how strong our platform is and our capacity to deliver continuity of care to dialysis patients across every site of care — from hospitals to patients' homes to our clinics. Our COVID response showcases the resilience and strength of our teammates and shows what a connected, multisite platform can do. Let me share a few examples to illustrate. To start, we’re leveraging our nationwide reach — including our people, capabilities and locations across the country — to launch and operate specialized clinics and to relocate dialysis patients who have tested positive for COVID or are suspected of having it, which has helped relieve strained hospital capacity. Working alongside the government, the dialysis sector has united to support uninterrupted care for dialysis patients by establishing separate cohort treatment space that other providers are able to use. Moving on, our position as a nationwide frontrunner in home dialysis has benefited the people we treat: backing the ongoing expansion of home dialysis through this emergency assists in delivering uninterrupted care for every patient, given that individuals might have shifted among receiving dialysis at home, in hospitals, or at a center as a result of the virus. Beyond that, we have leveraged our top-tier telehealth tools to broaden treatment for patients within the safety of their residences while preserving their connection to their caregiving team; backed by the government, we are currently employing that telehealth platform to provide additional assistance for in-center patient care. To wrap up, in the more than 900 hospitals where we provide essential services, we have managed to direct resources and reassign caregivers toward the places needing the greatest assistance in caring for patients and supporting our hospital partners. Now, I'd like to discuss a few of the patterns emerging, and in doing so, share what we anticipate regarding COVID's effects on the business over both the near and longer term. With respect to the path of the virus, we are seeing waves of COVID impact across geographies much like what you have come across in news coverage. At the outset, the CDC sought to have every patient who tested positive for COVID treated within the hospital. Yet as the pandemic continued to spread, the CDC quickly recognized that approach could not work, so it turned to providers like DaVita—which had focused on infection control well before COVID—to relieve pressure on hospitals and care for stable patients in an outpatient setting. At present, nearly 70% of DaVita patients who test positive for COVID or are suspected of having it receive treatment in one of our outpatient locations. Keeping up three sessions per week for these COVID-positive or suspected patients — whether they're in cohort status or in clinics — has been a truly extraordinary operational achievement, and through it all we've maintained care continuity for over 230,000 people who show no signs of the virus but are at risk because of multiple other comorbidities. How this plays out for our business in the near term is still fluid and to some degree unclear; even so, at this point we can reaffirm our 2020 guidance. That may sound different from what other providers have told you, since they could be facing volume or liquidity challenges stemming from the big decline in elective procedures. Dialysis, as everyone knows, is not something patients can skip—it's treatment that keeps them alive, and they need it several times weekly. Where we have less clarity is over the longer term. Our view is that COVID's economic effect on the business will lag behind the effect felt by the wider economy. The extent to which COVID hits our business will hinge mainly on how long this terrible virus persists and what it does to unemployment more broadly; in our view, those are the factors that would bear most heavily on volume and mix. On volume, because growth of the dialysis population is less certain given the possible effect of the virus on the late-stage CKD population and on the health status of ESRD patients we already serve. Turning to commercial mix—the insurance makeup of our patients might take a hit if the wider economy weakens. I'd also like to recognize how quickly the administration responded during this crisis. Working alongside the dialysis industry, it adjusted specific policies and regulations so we could more easily treat COVID-positive patients in cohort status or in clinics where that was needed. It also moved fast to send funds to health care providers, aiming to make sure patients—both uninsured and insured—can get the care they need throughout this crisis. Our reading of what the government intended with the relief fund is that it was meant to keep health care providers from shutting down, rather than to assist a company in hitting its earnings target. DaVita has provided care for our patients, the uninsured among them, and will keep doing so, without any need for this federal funding. So even though we have taken on costs that fit within the release fund's parameters under the Cares Act, DaVita has chosen to turn down this government financial support for now. Our view is that it's best for our company, our shareholders, and our countries when those dollars reach other people, organizations, or health care providers who truly need them. ESG has gotten more attention over the past year, and doing what's right matters. As we see it, this health care crisis presents an opportunity for companies to lead and to give back for the good of society at large, and we're pleased to do our part. Let me end with a thought on DaVita's culture. All through this crisis, our resilience has depended centrally on the fact that our frontline caregivers know they are part of something larger — that they feel it. They're genuine heroes, and they know our whole company — our village, as we put it — is doing everything possible to back them up. We recognize the future with this virus remains unpredictable, but we're grateful that our village is strong. I'll now hand things to Joel for an update on our Q1 results and a discussion of our financial outlook.

Joel Ackerman

executive
#3

Thank you, Javier. First, I'd like to express appreciation for every one of our teammates who gives selflessly of themselves to deliver life sustaining dialysis treatment to patients who are vulnerable. Being part of the DaVita Village makes me proud. Q1 came in strong, with COVID having a comparatively small effect. Full details appear in the press release, and I'm happy to take any questions during Q&A. My remarks will concentrate on financial matters tied to COVID. To begin, the degree of uncertainty we confront looking ahead is much greater than what we normally see. What's driving that includes how severe and how long the COVID pandemic lasts, the effect on the population we serve that could produce a reduction in treatment volume, and the effect on unemployment along with commercial health insurance coverage. Because of that uncertainty, projecting financial results is more difficult than it typically is, and the spread of possible outcomes is broader than typically. Treatment volumes have held reasonably stable thus far; through the remainder of 2020, we anticipate volumes will feel the effects of any shifts in mortality, transplant and/or new patient admits stemming from COVID. Turning to expenses, we are bearing higher costs stemming from extra compensation and reimbursement for certain teammates to help offset some of the personal financial consequences of the crisis, improvements to our overtime PTO and benefit policies, the creation of dedicated shifts for caring for patients with confirmed or suspected COVID, redistribution of teammates, machines and supplies across the country, labor hours required to screen patients and teammates entering our clinics, greater purchases and pricing of personal protective equipment for patients and teammates, larger investments in and utilization of telehealth, and development of educational materials for patients. Offsets to these expenses could include the suspension or sequestration starting May 1, which we expect will add roughly $50 million to our revenue in 2020, as well as other cost reductions in our business. At this point, we are maintaining our 2020 guidance ranges for adjusted earnings per share, revenue, operating income margins and free cash flow, while acknowledging the heightened uncertainty given the rapidly shifting dynamics surrounding COVID. COVID's longer-term effect remains uncertain and hard to quantify. In our view, the 2 main factors to weigh are growth and mix. On growth first, our long-term growth could be affected by shifts in mortality within both the late-stage CKD and ESRD populations because of COVID; that will hinge mainly on infection rates, base fatality rates, and the age and health status of the patients affected. Second, higher unemployment levels will probably mean fewer patients holding commercial insurance, which generates earnings headwinds given the higher reimbursement rates we receive from commercial insurance plans. The net impact can't be predicted at this time, but I'll point to 4 important dynamics. First, when you look at how sensitive our business is through a recession, we believe the peak level of unemployment matters more than the shape of the recovery. Yet a lot of our patients would rather keep their coverage for the near term, even though they may take longer to get back to work during a recovery. Second, in estimating peak unemployment, we should keep in mind that a substantial share of people counted in the unemployment figures are in fact furloughed and continue to receive health benefits from their employers. Those furloughed patients who do eventually return to work might see no interruption in coverage at all. Third, a meaningful portion of our commercially insured patients hold coverage that isn't linked to their present job. That covers patients with individual insurance and also patients on COBRA. This ought to help soften any potential shift in our mix tied to the rise in unemployment. Finally, should our patients lose employer-based coverage, several options are available to them, among them exchange plans, where many patients can obtain tax credits and cost-sharing reductions — something that wasn't available when we emerged from the 2008 recession — along with COBRA and Medicare and/or Medicaid. Turning to our balance sheet and cash generation, right now we don't foresee a material near-term negative effect from COVID. Out of an abundance of caution, during March we drew down $500 million from our revolving credit line, which shows up on our balance sheet as of the first quarter end. With our current cash balance and near-term outlook, we expect to repay the revolver before long; we also paused share repurchases in March and have bought back no stock since. For the near term, we intend to be cautious about capital deployment and will aim to preserve financial flexibility and liquidity given today's uncertainties. We believe our cash flow generation and our balance sheet leave us in a solid position to ride out the financial and operational challenges created by the current pandemic. That will let us keep concentrating on what matters most — the health and safety of our teammates and delivering high-quality care to our patients. With that, operator, please open the line for Q&A.

Justin Lake

analyst
#4

Thanks for all the detail. A few points. First, clearly a really strong opening quarter. Could you walk us through what you observed versus your own internal expectations? And perhaps break out what you'd consider core growth versus any items we should keep in mind?

Joel Ackerman

executive
#5

Absolutely. I'll handle that one. Hi, Justin, this is Joel. Three things stand out, though overall it was a solid quarter on many fronts in terms of what was notable. First, RPT came in somewhat above what we anticipated, though not enough to make me revise any of my thinking on the full year. Second, expenses were handled well across the board — I'd point to productivity, pharma. G&A is 3 items, even though the strength was widespread; and lastly, international contributed strongly. Some of that reflected solid underlying growth. International simply had a good quarter, but I'd point out there was roughly $10 million of FX gain in our — from our Asia joint venture, which is nonrecurring.

Justin Lake

analyst
#6

That's useful. You mentioned RPT came in somewhat above what was expected, though not enough to alter the outlook for the full year. Is there anything we ought to consider regarding a benefit in the quarter that won't repeat? Any specific item?

Joel Ackerman

executive
#7

Not really anything specific. That RPT figure will move around somewhat between quarters. So there's nothing we'd call out.

Justin Lake

analyst
#8

Now on the expense side — I mean, once more, it feels like I'm getting — is there a core growth figure you generally use, excluding the moving pieces? Since what I'm calculating lands somewhere in the teens.

Joel Ackerman

executive
#9

Honestly, this quarter is a difficult one to pin down. Do you mean Q1 compared with Q1?

Justin Lake

analyst
#10

Yes, that's on a year-over-year basis.

Joel Ackerman

executive
#11

Yeah. Yeah. Well, the first quarter of last year wasn't especially strong, and then Q2 picked up nicely. So there is — I'd say you saw some variability there; this year, the usual quarterly seasonality is going to be somewhat flipped around. Normally, Q1 is a weak quarter. This year, you have the positive calcimimetics, and then in the back half of the year, you'll see some negatives from valid initiatives and as the COVID impact grows. So I think, when you think about a full year number, the margin you're calculating there is — or the growth rate you're calculating there is something I would be hesitant to focus on.

Justin Lake

analyst
#12

All right, and before I get back into the queue, could you provide the calcimimetics benefit and how it impacted the first quarter, perhaps for both RPT and operating income? Then it appears CMS reduced the number in the second quarter. So what's the right way to think about that for the remainder of the year?

Joel Ackerman

executive
#13

Sure. For the full year, I'd say I wouldn't — I don't — I wouldn't alter anything we've stated regarding calcimimetics, which is $40 million to $70 million of OI for the full year. The Q1 figure was $35 million of OI benefit. The RPT figures, I'm searching for those, the RPT figure was $9.50 in Q1 and the cost per treatment, $4.90 and change. So $9.56 of RPT, $4.94 of cost per treatment.

Andrew Mok

analyst
#14

I just wanted to follow up about the commercial rates. If we look back to the last recession, it appears your commercial revenue mix fared better than your commercial treatment mix. Might that happen again, perhaps through higher negotiated rates on a smaller base of commercial patients? Should we expect more permanent job losses?

Javier Rodriguez

executive
#15

I'll take that one, Andrew. I think comparing is hard. At the close of the last recession, naturally, the dynamic was different. This one is extremely unique. So first, as Joel mentioned, we now have the exchanges. We therefore don't know what will happen there or how many people will choose the exchanges. We still have COBRA, and we still have all those people who have been furloughed. So when you consider this versus the last recession, when we didn't have a large number of people seemingly on pause or furloughed for a while, we don't know how that dynamic will unfold. Last time, there wasn't much change in the rate dynamic, meaning rate dynamics remained similar to what they had been previously. And I have nothing to inform me that would change.

Andrew Mok

analyst
#16

All right, that's great. And so, just a follow-up question regarding...

Javier Rodriguez

executive
#17

Is that a satisfactory response to what you asked?

Andrew Mok

analyst
#18

Yes, that's good. I just have a follow-up about home dialysis. Are you noticing any increase in interest among your patients in pursuing home therapy? And second, over the longer term, do you think this crisis might speed up the shift toward home dialysis?

Javier Rodriguez

executive
#19

Yes. It's an interesting dynamic. A lot of people are asking that very question. At this point — and again, it's so early in this — we don't know what the long-term implications will be, but for now, we saw a slight downtick, so a bit of weakness. But when you look at it, it's really the placement of catheters that affected it. And then once the administration deemed it essential, that began to pick up. In addition, as we discussed, our platform really matters, meaning a lot of patients start in center and then, through education, go home. Well, we saw that number decline a bit because we didn't have many educators and nonessential personnel in the centers, so we would not spread the virus; therefore, fewer of our patients in-center moved home. And so when you add it all together, there's still a lot of energy. We reached our 25,000-patient mark at home. And we think that over time, we will return to the patterns we saw pre-COVID, which is roughly 10% or so growth.

Kevin Fischbeck

analyst
#20

Great. I guess what I wanted to ask about is — earlier this year you guys announced what amounted to a sizable hiring push. And obviously you highlighted quite a few potential pressures and uncertainty as the year unfolds, including the effect on the economy. So I'm just trying to get a handle on what the point of that was, that big bump in hiring, and how you weighed taking on extra costs potentially going into a recession.

Javier Rodriguez

executive
#21

Yes. Thanks, Kevin. I think when it comes to hiring people, you've got to split it into 2 categories. One is the G&A that gets spread out across all the clinics, and then you have the frontline caregivers. And so what we announced, which was a big hiring, was for frontline caregivers; and so what you're seeing is that sometimes in times like this, when you've had a nursing shortage and you've had a robust economy, it's a great opportunity to have a stable workforce. And so that's really what you saw. We had openings across the country. And so we want to fill them now while there's a lot of people looking for jobs.

Kevin Fischbeck

analyst
#22

All right. So this is really about filling vacant roles rather than attempting to boost growth in a particular segment or anything along those lines?

Javier Rodriguez

executive
#23

That's right.

Kevin Fischbeck

analyst
#24

Alright, so I suppose there's been quite a bit of coverage in the media regarding hospital patients with COVID who require additional dialysis. Has that had any effect on your business at all — whether through running the hospital outpatient dialysis clinics yourselves, or hospitals attempting to empty out their dialysis clinics and perhaps sending volume in your direction? Does any of that dynamic exist?

Javier Rodriguez

executive
#25

Broadly speaking, the brief response is that it varies unpredictably depending on the geography. So in certain geographies where hospitals, owing to all the elective procedures, have experienced a significant drop in census, our acute has seen that too, provided COVID hasn't struck that region. Naturally, there are other regions where COVID is fairly active, and there we've observed a rise. Yet once you net it all out, it's nothing you'd detect in the economic model, if that's what you're getting at?

Kevin Fischbeck

analyst
#26

Yes. No, it's perfect. And then you brought up several of the headwinds surrounding the recession. Are there any offsets you can think of? I suppose you sort of said labor could be easier to find during a recession. How do you weigh the opportunity to save on costs against the possible revenue pressures from the recession?

Javier Rodriguez

executive
#27

Yes. Joel, do you want to take it?

Joel Ackerman

executive
#28

Right, so I think cost mitigation really breaks down into 2 ways of looking at it, and honestly it falls into 2 buckets. The first is what you'd naturally see happen during a recession — things like better productivity from reduced turnover, lower spending on training, and other salary-, wage-, and benefit-related items — so that's one bucket. Then the second is the levers we can pull on our own initiative to remove costs from the business, knowing that if mix pressure or volume pressure shows up, we have options available. Our business model is resilient. So there are steps we could take that would offset some of those pressures too. That means part of it is natural and part of it is proactive.

Kevin Fischbeck

analyst
#29

I mean, should we take anything from the fact that you brought up the headwinds without those offsets? During a recession, would you expect growth to fall perhaps below the usual OI growth range? Or is it possible to still grow inside that range while a recession is going on?

Joel Ackerman

executive
#30

What I'd say is that it's too soon to know. There is simply so much we don't yet understand about how this recession will probably unfold — what peak job loss will look like, how much of it is genuine job loss as opposed to just furloughs, and how things will progress? And how much could we offset when we think about mix. So what I'd say is that it's too soon to know how much of that we would be able to offset from a cost standpoint.

Ben Mayo

analyst
#31

I'd like to piggyback on what Kevin asked about the hospital segment. That's an area where you folks have achieved pretty impressive expansion over the last several years. My understanding is the count of hospitals you cover hasn't really moved, yet the revenue tied to them has grown at a double-digit clip for a long stretch. Could you walk us through some of what's behind that, and also how your contracting with hospitals works?

Javier Rodriguez

executive
#32

Absolutely. Let me offer a bit of detail on that and see. Broadly speaking, it's an extremely demanding business given its cyclical nature — demand from hospitals swings up and down around the clock, 24/7. That makes it quite difficult for new players to get in. That's precisely where our platform stands out, and hospitals recognize the benefit of the network and of the float pools, which let you actually field a team to care for the patient; so what we've observed is that many hospitals appreciate the value we offer; and naturally, that gets reflected in both price and service. As a result, we've watched that platform expand considerably.

Ben Mayo

analyst
#33

All right. So when I think about how many hospitals there are — if it's 900 and revenue is rising 13% — is that the right way to think about the organic growth in that business?

Javier Rodriguez

executive
#34

Joel, could you split out revenue versus price? Or would we rather not reveal that?

Joel Ackerman

executive
#35

Of course. That figure isn’t part of what we report publicly, though this line has been expanding at a quicker pace than the main business, even while remaining quite small — and I’d note too that its margins tend to run lower.

Ben Mayo

analyst
#36

All right. I have one more question regarding calcimimetics. A lot of the data shows what seems like a steady, I think, increase in the use of Parsabiv versus Sensipar, and the ASP is considerably greater compared with Sensipar. Could you perhaps walk us through the economics of the two and what your split is at present?

Joel Ackerman

executive
#37

I don't believe we have disclosed that split in detail; in — when you consider the jump in calcimimetics profitability that began 2 years ago and then continued last year and this year, it's mostly driven by the oral and the gap, as you know, between the way ASP declines and the way our pricing declines. I think, as we look ahead, clearly, since we're — since the tobacco period is nearing its end, the profitability of calcimimetics is disappearing. I think the key question for us is 2021. And the matter between the oral genetic and the IV is how does the bundling work? And how will CMS reimburse us and what — is it by drug, by patient or some other methodology, and that's really what will shape the economics.

Javier Rodriguez

executive
#38

Just to quickly reiterate that point, Whit: it's the physicians who decide between IV and oral, so ultimately they may have a preference. At the moment, data is limited, and we're aware that the IV option costs considerably more. As a result, physicians feel that fiduciary duty to choose what is clinically equivalent, or what seems equivalent — clinical equivalence at a far lower cost.

Ben Mayo

analyst
#39

Okay. No, that helps. And maybe just one final question, going back to what was said about volumes, and trying to figure out how COVID is going to affect this patient population; and Javier, you brought up looking at some of the CKD stage 4, 5 patients. And clearly, there's going to be some impact on your census today. I wonder if maybe you could expand a bit more on how you're thinking about what the longer-term effect of COVID-19 could be on the ESRD population?

Javier Rodriguez

executive
#40

Sure. And I'll do my best to be helpful, Whit, but as you can imagine, there are just a lot of dynamics at play, and it's still pretty early in the game. So the first thing, and probably the biggest disclosure, is that it all hinges on how long the virus lasts and how severe it is. And of course, whether we get another wave and all those sorts of things. But if you assume, just for the sake of argument and to be an optimist here, that there won't be another wave, you have to start looking at, okay, did the virus actually affect CKD patients who would have been on dialysis? And if so, by how much and to what magnitude? Second, if you were looking for something that could raise volumes, it's whether the virus actually caused damage to people who wouldn't otherwise have had some kidney damage. And so it's too early to tell. On the other side, of course, the preferred kidney replacement therapy would be a transplant. And if you put a transplant into categories, there were the living donors and the deceased donors. And what we're seeing right now, while the virus is active, is that the living donors are coming down because of the risk of infection. And so there would be some potential changes in those numbers that would increase the volume of dialysis patients. So those are some of the gives and takes that are going on. We don't know how it will all net out. And so we're keeping a close eye on it.

Pito Chickering

analyst
#41

Just a few ones here. Productivity came in strong this quarter. Could you discuss what drove productivity? Was it consolidation and shutting down centers from last year? It sounds like it wasn't a shift to PD or home therapies; so what other factors caused productivity to rise?

Javier Rodriguez

executive
#42

Yes. There's nothing specific I'd call out, other than obviously labor is our biggest cost item; it's something we devote a lot of time to focusing on. And it's simply something we have to manage well over the long term in order to handle the fact that our RPT increases sit below inflation. So it's just blocking and tackling that we keep on excelling at.

Pito Chickering

analyst
#43

All right. Regarding COBRA benefits, has anything changed when it comes to how long individuals may remain on COBRA compared with earlier recessions?

Javier Rodriguez

executive
#44

As far as I understand it, I am not aware of any COBRA expansion, though patients in our population are able to add 11 months owing to disability; there is therefore a disability extension. That means, in effect, coverage for our patient population could last 29 months. Whether a COVID exception exists, I do not know.

Pito Chickering

analyst
#45

All right. From a macro standpoint, there's quite a bit of uncertainty right now. As we head into 2021, what effect can Medicare Advantage have for your patients who want to lower their out-of-pocket costs? And do you think that uncertainty could add to or fuel more people adopting Medicare Advantage at this point?

Javier Rodriguez

executive
#46

Well, opinions on your question vary quite a bit. Ultimately, it's pure speculation, since we simply don't know. This kind of choice is highly individual and personal. That said, broadly speaking, the reason someone would choose MA is that it comes with a max out of pocket and offers some additional benefits. And the reason someone would remain in Medicare is that they're accustomed to it; it offers what is essentially an almost unlimited network, so to speak, and doesn't carry the restrictions. If you have secondary coverage, that really assists with your out-of-pocket expenses. So what we've stated before, and we keep stating, is that we have no information that would let us conclude anything other than our population will likely mirror the general population. The sole reason we're so different is that this is the only population that wasn't permitted to enroll in Medicare Advantage. So the only people there are those who enrolled before their kidneys failed. And so there's going to be open enrollment. And now the question becomes, what will the environment look like in the fall? Will patients be able to sit down with someone? Will a website be available to them? Will they be more nervous, more fatigued? Is the virus still with us? Or are we in a more normal situation? And the short answer is we don't know any of that. So I'm just giving you the data on how someone would pick one versus another.

Pito Chickering

analyst
#47

Great. Then, as a final question, purely from a modeling standpoint: you went through several costs that will carry through into 2Q. Can you put any kind of dollar figure on that? And how much should we assume these additional costs get layered in during 2Q?

Joel Ackerman

executive
#48

Yes. So, Pito, predicting this is genuinely difficult — there are many moving parts. And again, there's uncertainty regarding how long the pandemic lasts and how severe it is, et cetera, et cetera. I'd also mention that when we consider how we've modeled things across the different scenarios we've worked through, we've by and large assumed the peak is behind us. We're roughly at the peak or past it. We have a whole bunch — a whole range concerning the speed at which the pandemic starts to taper. But a second wave is not something we've modeled in; so as you consider our guidance and what we're comfortable with, I just wanted to flag that. On specific numbers, our thinking is that April's figure will land somewhere in the $30 million to $40 million range. It seems reasonable to expect May to fall in that same range, and then, again, depending on how the pandemic unfolds, we'd expect it to begin tapering down.

Pito Chickering

analyst
#49

Okay. And actually, one last thing, sorry, about share buybacks. Look, you aren't taking any government grants right now; and since, as you said, you see this as basically past the peak at this point. When do you figure you'll consider buying back shares again? Is it more something for the third quarter? Or do you go into June, things look better, and you start repurchasing shares then?

Joel Ackerman

executive
#50

Yes. So I can't give you a date, because we don't have one. Given all the uncertainty, we will definitely be careful with deploying capital. I think we'll probably maintain a higher liquidity level than we did previously. So it's hard to say when — how we'll approach share repurchases going forward, and when that caution might ease up a bit.

Gary Taylor

analyst
#51

Only a handful. Just so I'm clear about what you said last, Joel — the $30 million to $40 million, was that for April and May? And was that extra expense — extra operating expense you're describing as plausible?

Joel Ackerman

executive
#52

Right; that's the added operating expense we'd anticipate in connection with COVID.

Gary Taylor

analyst
#53

Also, when it comes to giving back the Cares Act money, does that apply only to the initial $50 billion that has already gone out? Have you reached any conclusion regarding the entire $175 billion across the 2 provider funds? Or is that still to be determined based on how circumstances unfold?

Javier Rodriguez

executive
#54

Maybe I'm getting bogged down in specifics, so please tell me if I've got this wrong, Joel, since I could be combining pools together and I'm not, but in my mind the Cares Act relief fund is what this is. And that's the money we concluded matched the government's intent, which naturally different people can read in different ways. Yet as we saw it, those funds were a safety net, meant for those who required that cash since the economic harm was so extreme that they couldn't keep operating. And so although it's — as you can see from the figures Joel provided, we've got large cost increases. And incidentally, those figures you mentioned, the $30 million to $40 million, are per month. So we have incurred substantial expenses. We don't believe that was what the money was meant for, so we will return it.

Gary Taylor

analyst
#55

All right. Then I noticed a couple of line items shift on the income statement, Joel. Could you speak to that — I realize equity investment income came in at nearly $18 million for this quarter, which is above the typical level, while other income, reduced by interest expense, swung to a negative $4 million and change. Those two both seemed somewhat out of the ordinary. Is there anything worth flagging there?

Javier Rodriguez

executive
#56

Yeah; regarding equity income, the largest piece is the $10 million of FX on the Asia joint venture that I mentioned. Another element here involves the deconsolidation of several of our clinics effective 1/1/2020. You'll find the specifics in the 10-Q. It has no effect on EPS, but it does take what was OI and converts it into a — it converts — it shifts it over to equity income; previously it ran through revenue and cost, and now it moves to equity income, and then there is an offset down at the NCI level. So those are the main items I'd flag there. As for other income, there was a separate FX loss tied to the international business, roughly $9 million; so those are the key things I'd point out.

Matt Larew

analyst
#57

Actually, Javier, I want to revisit the tariff dollars one more time. Obviously, when you announced getting those grant dollars—April 13, I think that was—you'd mentioned you were thinking about keeping hold of it. I'm just wondering: did extra guidance or regulation from the government factor into what you decided? Or was it something the Board and management chose to do on their own initiative? I'm just trying to follow the timeline from April 13 up to today.

Javier Rodriguez

executive
#58

Yes. It was the second one—a proactive call by the Board and management. You could also argue quite convincingly that the intent there was to cover costly COVID-related items—and we have plenty of those, such as PPE, extra staffing, overtime, and everything else we've gone over on this call. On the other end, the government—which deserves full praise—essentially said: we've never dealt with anything like this, so we're going to send out funds to safeguard Americans' well-being, and we'll sort out the details afterward. But we don't require time to sort anything out. We're certain we're not in a position of being the safety net. Our aim is to act ahead of time, ensuring the government can see who is in a position to return funds, allowing that money to be redirected swiftly toward those genuinely in need—that's the principle behind our decision.

Matt Larew

analyst
#59

Yeah, that's fair. And actually — this morning you put out an announcement regarding DaVita Ventures, DaVita Venture. I'm just curious whether you have any targets in mind for that group. And given that announcement came out this morning, I'd like to give you a chance to speak to it.

Javier Rodriguez

executive
#60

Yes. Thanks, Matt; DaVita Ventures, DaVita Venture has us really excited. Essentially, plenty of entrepreneurs keep bringing out all sorts of great things, and they ask whether they can partner with us. So this venture group is now out there and truly creating demand. Our aim is to be the partner of choice. And as we discussed around capital markets, we're growing from a dialysis company into a full kidney care company. That means we'll need particular technologies and partners spanning diagnostics to pharmaceuticals and other areas in transplant, so we want to be out there, and it has us really excited.

Joel Ackerman

executive
#61

The one additional point I would make there is that when you consider how large these investments are, our expectation is that they will probably land in the single-digit millions. And viewed against our free cash flow, that will not alter the figure at all. So it is comparatively small.

Lisa Clive

analyst
#62

Just one question about legislation in Washington. Obviously, D.C. is occupied with COVID-19, and that is the primary focus. But do you believe the COVID-19 pandemic increases the chances that the PATIENTS Act might get passed? Do you have any thoughts on just how live that bill is in Washington right now? And a follow-up on COBRA — from what I understand, even though there is an 11-month disability extension, nearly all patients leave COBRA at 18 months, because beyond that point they go from paying 102% of the premium to 150%. So is it fair to assume that the only people who remain on COBRA are those with cap premium support?

Javier Rodriguez

executive
#63

Let me grab the — Lisa, first of all, you've gone beyond what I know about COBRA. And so Joel, I don't know whether you know that technical piece. In the...

Lisa Clive

analyst
#64

Put another way, I suppose...

Joel Ackerman

executive
#65

That, I can't tell you.

Lisa Clive

analyst
#66

All right. I suppose another way to put the question is this: if we do — considering the jobless figures we've been observing nationwide, if COBRA ends up accounting for a considerably larger share of your — well, if many more patients wind up covered by COBRA. What I'm really trying to get at is how long those people will actually stay on it. So any perspective you could offer on that would be useful.

Javier Rodriguez

executive
#67

Right. I don't. And so — we could follow up with you, but beyond that I have nothing further to share on it, sorry. There was a second part to your question, though, Lisa?

Lisa Clive

analyst
#68

Regarding the PATIENTS Act — and yes, this is both about whether COVID-19 has had any effect and about the broader conversations happening in Washington on that topic.

Javier Rodriguez

executive
#69

Well, let me just say that, broadly speaking, I haven't had the nerve to raise any questions, because obviously everyone has been fully committed to this COVID crisis. My hope is that policymakers recognize the worth of integrated care and appreciate how strong it can be to link the places where care is delivered and to have that done in an organized way, since that really helps. Take DaVita as an illustration: the way we were set up with PPE, the way we could launch cohorting centers, the way we could support our teammates with child care and other things — we clearly witnessed that in other areas, yet we did not witness it among a lot of the smaller players. So our hope is that the government sees that organizing resources and building capabilities across the country is also quite valuable, and that linking the sites of care together with the technology could be good for the system and for the patients. So we'll see what happens after COVID.

Justin Lake

analyst
#70

I have a few additional ones here. First off, Joel, I just wanted to follow up on what you told Pito about costs. I get that you'd rather not put a specific figure out there. But during your prepared remarks, you sort of laid out that there are COVID-related costs, and you gave us new costs in April and May that were not insignificant. You brought up the $50 million benefit from sequestration, and you also mentioned other cost reductions. So I'm curious — when you bundle all of that together, it looks like a headwind, excluding potentially the other cost reductions. But I'm just trying to think about it relative to where you were, kind of, back in February when you gave the original guide or updated it. How should we think about the net of those impacts? In your mind, is that an additional headwind? Or can you kind of offset the incremental COVID cost?

Joel Ackerman

executive
#71

So the way I'm thinking about it is this: if you start with strong performance in the core in Q1, and you offset that with the COVID costs and then add back sequestration, we kind of feel like — and then there are some natural costs that come down, T&E being a simple example of that. We feel like net-net, we wind up with a potential headwind that we're comfortable absorbing without changing our guidance; so if you want to think about how do we get to maintaining our guidance, strong Q1, the negative of COVID offset by the $50-ish-million from the sequestration suspension and some other cost offsets.

Justin Lake

analyst
#72

Could you give me a specific figure on how much stronger Q1 came in compared with what you had internally expected when you put together the guidance for the year?

Joel Ackerman

executive
#73

No, I won't be pinned down on that.

Justin Lake

analyst
#74

Okay. So a few fresh payment probes appeared in the 10-Q you just filed. I understand that's part of the cost of operating in dialysis, and across the 20 years I've followed the company, they really haven't added up to much; but I just wanted to check whether there's anything new or different we ought to factor in? And with those, and what was disclosed there, I suppose, in New Jersey and California?

Javier Rodriguez

executive
#75

No. What I would say is that naturally we treat them extremely seriously, and we have just completed our corporate integrity agreement. We've been doing this for five years now, and our goal remains to be a leader—to demonstrate both the spirit of compliance and the letter of the law. So whenever we receive one of these, it's a letdown. And naturally, they can arrive through all sorts of channels, whether investigations or inquiries. You'd like to think that after they observe our practices, they'll be content with what they find. But each time one comes in, I can tell you from a personal standpoint, I feel extremely frustrated, since compliance is something we discuss and practice every single day. So there's nothing further I can add on that, Justin.

Justin Lake

analyst
#76

Got it. Then I have a few quick number questions. You said that a large share of your commercial patients have coverage not linked to a job. I'm just wondering whether you could give us even a rough figure there. Would it be half? A quarter? 2/3? Something along those lines you're able to share?

Joel Ackerman

executive
#77

Yeah. So there are actually 2 pieces to that. One is COBRA, and the other is patients on the exchanges. I believe the figure sits in the 25% to 30% kind of range.

Justin Lake

analyst
#78

All right, so those 25% to 30% aren't connected to employment?

Joel Ackerman

executive
#79

Correct.

Justin Lake

analyst
#80

Or is it connected to COBRA and the exchanges, all right. And regarding the first quarter, what would you estimate the — or could you provide a figure for how much you believe the additional day in that quarter contributed to operating results?

Joel Ackerman

executive
#81

No, that — wait a moment. I'll have that figure for you before we end the call.

Justin Lake

analyst
#82

All right. And then, regarding California AB 290 — I realize you mentioned that coming in below what you'd previously said, correct? The $25 million to $40 million figure you first provided, it's going to be smaller. Should we now assume that simply drops to 0? Or do you believe some impact could still remain there?

Javier Rodriguez

executive
#83

Rather than hand you a figure, here's what I can say: because of COVID, the injunction held. In plain terms, that essentially means the case has been extended, so it's unlikely to matter much unless — given the timing, until the fourth quarter, depending on how the case unfolds, and it could then carry into Q1 of 2021. So the number hasn't changed; what's moved is the timing. And naturally, the outcome remains unknown.

Justin Lake

analyst
#84

All right, and one final thing — on payer mix for the quarter, Javier, I believe you mentioned it was down. Could you give us some specifics on that, or tell us where you finished the quarter in terms of commercial mix?

Javier Rodriguez

executive
#85

I think we've published it, so it's fine for me to say it, isn't it, Joel?

Joel Ackerman

executive
#86

That doesn’t sound right to me. Justin, regarding that—nothing meaningful happened in the movement during the quarter. If we believe it matters, we’ll flag it each quarter, but nothing material was there.

Justin Lake

analyst
#87

So are we still looking at roughly the 10% range, more or less?

Joel Ackerman

executive
#88

Yes.

Jeff Gates

analyst
#89

Yes, I have a couple of questions. First, I noticed that volume was the strongest quarter you've had in a few quarters; and I'm just wondering whether there are — do you see any signs of an uptick in volume, and what might be driving that? That's number one. And number two, is this environment going to force you to do fewer de novos? Or will you not be able to do as many de novos, so will your capital budget come down at all?

Javier Rodriguez

executive
#90

Do you want to take that one, Joel?

Joel Ackerman

executive
#91

Absolutely. We had a solid NAG quarter, there's no question about that. I wouldn't highlight anything in particular at this point. I also wouldn't say we're at the point of claiming success on some of the work we've been doing to get NAG moving higher again, and there was definitely a small amount of noise toward the end of the quarter, so there's nothing to point to there. On de novos, I think we'll hold off and see how industry volumes develop and what happens on the home side, but there's certainly a possibility that if there's an overall NAG headwind stemming from COVID and perhaps a faster shift toward home, then I think you'd see a potential decline, not only in our de novos but in industry de novos as well, and that would reduce the capital budget.

Jeff Gates

analyst
#92

Are you running into any difficulty building the centers you had planned?

Joel Ackerman

executive
#93

Well, I would say that for 2020, it depends on how long the various state shutdowns go on — we might see our capital spend come down somewhat. It's just that a few projects we physically cannot complete at the moment, but that will hinge on how long things continue.

Javier Rodriguez

executive
#94

Justin, before I wrap up, let me just say that the effect of one day comes to roughly $10 million to $15 million.

Javier Rodriguez

executive
#95

Alright, a few closing thoughts from me. First, thank you for all of the support. Second, I'm not sure words can capture how proud our team makes me. What I've witnessed over these last 60 days — the beauty and the dedication — is honestly difficult to express. The fact that our government, our competitors, and we set everything aside, banded together, and collaborated to care for our patients is just beautiful, beautiful, beautiful. Our clinical focus and infection control expertise have been critical in getting us through this virus. Third, this crisis has made clear how important our platform is for connecting sites of care. The resilience of our team and our business model has been beautiful, beautiful, beautiful. Financially, we have a strong balance sheet and a proven track record of cost management. And finally, I genuinely believe that philosophically, the time has come for the country to come together, and we're glad to do our part; so thank you for your interest in our company, and we'll speak again next quarter.

Operator

operator
#96

Thanks, speakers. Ladies and gentlemen, that brings DaVita's First Quarter 2020 Earnings Call to a close. You're free to disconnect now. Thanks for joining us, and have a wonderful day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.